Stewart Landau, MD
Urology · American Fork, UTNPI 1174559728
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Dendreon Pharmaceuticals LLC accounts for 61.9% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $16,994, more than ten times the $599 reported in 2019. Among urology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $59.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$17K
- Sanofi$2K
- Astellas Pharma US Inc$1K
- Pfizer$1K
- AstraZeneca$1K
- Johnson & Johnson$966
- plus $4K from 33 others
What the payments were for
- Consulting fees$2,73810%
- Speaking & faculty fees$12,03444%
- Travel & lodging$1,3055%
- Food & beverage$10,83940%
- Education$4332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 90 | $16,938 |
| Sanofi | 2 | $1,832 |
| Astellas Pharma US Inc | 59 | $1,381 |
| Pfizer | 64 | $1,165 |
| AstraZeneca | 12 | $1,146 |
| Johnson & Johnson | 25 | $966 |
| Sumitomo Pharma America, Inc. | 47 | $669 |
| Bayer | 18 | $510 |
| Accord Healthcare, Inc. | 12 | $335 |
| Amgen | 13 | $321 |
| AbbVie(2 entities) | 18 | $296 |
| Myovant Sciences Inc. | 21 | $248 |
| Urovant Sciences Inc | 8 | $161 |
| Procept Biorobotics Corporation | 2 | $141 |
| Endo Pharmaceuticals Inc. | 9 | $140 |
| Myriad Genetic Laboratories, Inc. | 8 | $119 |
| Travere Therapeutics, Inc. | 8 | $111 |
| Antares Pharma, Inc. | 7 | $102 |
| Telix Pharmaceuticals | 2 | $73 |
| Merck | 4 | $73 |
| Foundation Medicine, Inc. | 4 | $59 |
| Janssen Scientific Affairs, LLC | 2 | $58 |
| Urogen Pharma, Inc. | 3 | $56 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $43 |
| Coloplast | 1 | $42 |
| Blue Earth Diagnostics | 2 | $41 |
| Endo USA, Inc. | 2 | $34 |
| Tolmar, Inc. | 2 | $33 |
| Novo Nordisk | 1 | $30 |
| Tolmar Pharmaceuticals, Inc. | 2 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Civco Medical Instruments | 1 | $24 |
| Novartis | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,349 in reported general payments places this provider in the 90th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 486 | $6,723,247 |
| ErleadaApalutamide | 57 | $794,323 |
| OrgovyxRelugolix | 151 | $395,866 |
| Ibandronate Sodium | 177 | $5,314 |
| Megestrol Acetate | 44 | $2,279 |
| Gabapentin | 19 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $1,381 | $6,723,247486 claims |
| Johnson & JohnsonErleada | $966 | $794,32357 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $669 | $395,866151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 96 urology providers in Utah.
Other urology in American Fork
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Sean HendersonAmerican Fork$21K
- Daniel CahoonAmerican Fork$18K
- Steven GangeSlc$1.5M
- William BrantSalt Lake City$290K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Jeffrey SparenborgProvo$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.